Bio-Rad Laboratories Announces Executive and Director Changes
Ticker: BIO-B · Form: 8-K · Filed: Jul 28, 2025 · CIK: 12208
| Field | Detail |
|---|---|
| Company | Bio-Rad Laboratories, Inc. (BIO-B) |
| Form Type | 8-K |
| Filed Date | Jul 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, cfo-appointment
TL;DR
Bio-Rad shakes up C-suite & board: New CFO, directors appointed effective immediately.
AI Summary
Bio-Rad Laboratories, Inc. announced on July 28, 2025, several key executive changes. The company elected new directors, including Dr. Michael J. Gelb and Ms. Susan J. Noack, and appointed Mr. John W. Smith as the new Chief Financial Officer, succeeding Mr. Michael J. Zody. These changes are effective immediately.
Why It Matters
Changes in key leadership roles like CFO and board composition can signal shifts in company strategy, financial oversight, and future direction.
Risk Assessment
Risk Level: medium — Executive and director changes can introduce uncertainty regarding future strategy and financial management.
Key Players & Entities
- Bio-Rad Laboratories, Inc. (company) — Registrant
- Dr. Michael J. Gelb (person) — Newly elected director
- Ms. Susan J. Noack (person) — Newly elected director
- Mr. John W. Smith (person) — Newly appointed Chief Financial Officer
- Mr. Michael J. Zody (person) — Outgoing Chief Financial Officer
- July 28, 2025 (date) — Effective date of changes
FAQ
Who are the newly elected directors?
Dr. Michael J. Gelb and Ms. Susan J. Noack were elected as new directors.
Who has been appointed as the new Chief Financial Officer?
Mr. John W. Smith has been appointed as the new Chief Financial Officer.
Who is the outgoing Chief Financial Officer?
Mr. Michael J. Zody is the outgoing Chief Financial Officer.
What is the effective date of these changes?
The changes are effective immediately as of July 28, 2025.
What items are being reported in this 8-K filing?
This 8-K reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, other events, and financial statements and exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 28, 2025 by Dr. Michael J. Gelb regarding BIO-RAD LABORATORIES, INC. (BIO-B).